WS #10572

03:56→04:22 UTC

From 496 msgs · 5 key-dev

MoonLake Immunotherapeutics priced an upsized $200M public offering at $20 per share, a biotech capital raise.

MoonLake Immunotherapeutics Public Offering

MoonLake Immunotherapeutics priced an upsized $200M public offering at $20 per share, a biotech capital raise.